Biotechnology specialist GeoVax (NASDAQ: GOVX ) — which focuses on developing immunotherapies and vaccines against cancers and infectious diseases — just announced a partnership with global clinical research organization Allucent . The main purpose behind the agreement is to conduct a Phase 2b clinical trial of GeoVax’s next-generation Covid-19 vaccine. Now GOVX stock is popping higher on the news, with shares up more than 110% today before paring back some of the gains.
According to a press release, the company previously disclosed that it was a recipient of an award via the Rapid Response Partnership Vehicle ( RRPV ) for the development of its GEO-CM04S1 Covid vaccine. The Biomedical Advanced Research and Development Authority (BARDA), which broadly falls under the U.S.
Department of Health and Human Services, funds the RRPV program. Among the top priorities of RRPV is to respond to emerging situations dynamically and quickly. Per the agreement with Allucent, GeoVax “will sponsor a 10,000-participant, randomized, Phase 2b double-blinded study to evaluate the relative efficacy of GEO-CM04S1” compared to an already approved Covid vaccine.
The key advantage with GEO-CM04S1 is that it delivers multiple antigens to a patient’s immune system in just one dose. Compelling Relevance Is Moving GOVX Stock GeoVax Chairman and CEO David Dodd laid out the bullish case for GOVX stock, stating the following about the partnership news: Likewise, Allucent Chairman and CEO Mark Go.
